drugset / Trial / NCT03034356

Reducing Hippocampal Hyperactivity and Improving Cognition in Schizophrenia

NCT03034356

Phase 1/2 Completed 67 enrolled VA Office of Research and Development
RandomizedCrossoverTriple-blindOther

Summary

This study plans to learn more about the effects of levetiracetam (LEV) on brain activity and cognition in schizophrenia and schizoaffective disorder. Levetiracetam is an anti-seizure drug, also called an anticonvulsant.

Timeline

Start
2018-09-01
Primary completion
2024-06-30
Completion
2024-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Levetiracetam Other / unclassified 125 mg Oral

Indications